Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03VBJ
|
||||
| Former ID |
DIB018913
|
||||
| Drug Name |
ATPO
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [467487] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C11H19N2O7P
|
||||
| InChI |
InChI=1S/C11H19N2O7P/c1-11(2,3)8-6(4-7(12)10(14)15)9(13-20-8)19-5-21(16,17)18/h7H,4-5,12H2,1-3H3,(H,14,15)(H2,16,17,18)
|
||||
| InChIKey |
AGSOOCUNMTYPSE-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
6801642, 7978739, 9591859, 15024800, 17404655, 24278239, 47574473, 50105823, 50105824, 51430224, 53777198, 57357185, 85230920, 90340593, 90341573, 92303690, 103228586, 103947820, 113155523, 121360850, 121361244, 124749440, 124879272, 125662173, 127404463, 162249220, 163564046, 163564543, 178100963, 230259432
|
||||
| Target and Pathway | |||||
| Target(s) | Glutamate receptor 2 | Target Info | Antagonist | [543828] | |
| Glutamate receptor 4 | Target Info | Antagonist | [543830] | ||
| Glutamate receptor 3 | Target Info | Antagonist | [543829] | ||
| Glutamate receptor 1 | Target Info | Antagonist | [543827] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Circadian entrainment | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Dopaminergic synapse | |||||
| Amphetamine addiction | |||||
| Nicotine addictionhsa04024:cAMP signaling pathway | |||||
| Long-term potentiation | |||||
| Long-term depression | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| Nicotine addiction | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | N-cadherin signaling eventsephbfwdpathway:EPHB forward signaling | ||||
| Reactome | Trafficking of AMPA receptors | ||||
| Trafficking of GluR2-containing AMPA receptors | |||||
| Unblocking of NMDA receptor, glutamate binding and activationR-HSA-204005:COPII (Coat Protein 2) Mediated Vesicle Transport | |||||
| Unblocking of NMDA receptor, glutamate binding and activation | |||||
| Cargo concentration in the ER | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic CellWP666:Hypothetical Network for Drug Addiction | |||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Amyotrophic lateral sclerosis (ALS) | |||||
| BDNF signaling pathway | |||||
| References | |||||
| Ref 543827 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 444). | ||||
| Ref 543828 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 445). | ||||
| Ref 543829 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 446). | ||||
| Ref 543830 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 447). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.